Patents by Inventor Valerie Azoulay

Valerie Azoulay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031622
    Abstract: An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 3, 2022
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Adel PENHASI, Avi Avramoff, Maxim Gomberg, Valerie Azoulay
  • Publication number: 20180271790
    Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
    Type: Application
    Filed: October 4, 2017
    Publication date: September 27, 2018
    Applicant: Dexcel Pharma Technologies Ltd.
    Inventors: Adel PENHASI, Avi AVRAMOFF, Maxim GOMBERG, Valerie AZOULAY
  • Publication number: 20160113878
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Application
    Filed: January 6, 2016
    Publication date: April 28, 2016
    Applicant: DEXCEL LTD.
    Inventors: Raffael Lahav, Valerie Azoulay
  • Patent number: 9023391
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: May 5, 2015
    Assignee: Dexcel Ltd.
    Inventors: Valerie Azoulay, Erica Lahav
  • Publication number: 20140178469
    Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
    Type: Application
    Filed: October 15, 2013
    Publication date: June 26, 2014
    Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Adel PENHASI, Avi AVRAMOFF, Maxim GOMBERG, Valerie AZOULAY
  • Publication number: 20120244219
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Application
    Filed: April 26, 2012
    Publication date: September 27, 2012
    Inventors: RAFFAEL LAHAV, ERICA LAHAV, VALERIE AZOULAY
  • Publication number: 20110038933
    Abstract: A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
    Type: Application
    Filed: May 5, 2009
    Publication date: February 17, 2011
    Applicant: DEXCELL LTD.
    Inventors: Valerie Azoulay, Avi Avramoff, Adel Penhasi, Maxim Gomberg
  • Publication number: 20070196485
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Application
    Filed: April 17, 2007
    Publication date: August 23, 2007
    Applicant: DEXCEL LTD.
    Inventors: Raffael Lahav, Erica Lahav, Valerie Azoulay
  • Patent number: 7255878
    Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: August 14, 2007
    Assignee: Dexcel Ltd.
    Inventors: Erica Lahav, legal representative, Valerie Azoulay, Raffael Lahav, deceased
  • Publication number: 20070065513
    Abstract: A stable composition comprising a substrate comprising lansoprazole (preferably in the base form), without any alkaline agent; a subcoating layer containing alkaline agent; and an enteric coating layer. The substrate is preferably an inert core with an active layer (containing lansoprazole) layered over it.
    Type: Application
    Filed: November 1, 2004
    Publication date: March 22, 2007
    Inventors: Avi Avramoff, Valerie Azoulay